Macquarie Group Ltd. Increases Stake in Haemonetics Co. (NYSE:HAE)

Macquarie Group Ltd. boosted its stake in Haemonetics Co. (NYSE:HAE) by 20.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 134,327 shares of the medical instruments supplier’s stock after purchasing an additional 22,652 shares during the period. Macquarie Group Ltd. owned about 0.26% of Haemonetics worth $16,165,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Alpha Windward LLC bought a new stake in shares of Haemonetics in the 2nd quarter worth approximately $29,000. Financial Gravity Wealth Inc. bought a new stake in shares of Haemonetics in the 2nd quarter worth approximately $40,000. Harvest Fund Management Co. Ltd bought a new stake in shares of Haemonetics in the 2nd quarter worth approximately $42,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Haemonetics in the 2nd quarter worth approximately $90,000. Finally, CSat Investment Advisory L.P. bought a new stake in shares of Haemonetics in the 2nd quarter worth approximately $143,000. 99.04% of the stock is currently owned by institutional investors and hedge funds.

A number of equities research analysts have recently weighed in on the company. Morgan Stanley lifted their price objective on Haemonetics from $128.00 to $148.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Barrington Research reiterated an “outperform” rating and issued a $139.00 price objective (up from $116.00) on shares of Haemonetics in a research report on Wednesday, August 7th. JMP Securities lifted their price objective on Haemonetics to $145.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 7th. ValuEngine lowered Haemonetics from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Jefferies Financial Group lifted their price objective on Haemonetics from $125.00 to $140.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $140.67.

In other Haemonetics news, VP Dan Goldstein sold 475 shares of Haemonetics stock in a transaction on Friday, August 9th. The stock was sold at an average price of $133.23, for a total transaction of $63,284.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO William P. Mr. Burke sold 7,164 shares of Haemonetics stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $125.80, for a total value of $901,231.20. The disclosure for this sale can be found here. Insiders have sold 61,836 shares of company stock worth $8,391,195 over the last 90 days. 1.32% of the stock is currently owned by corporate insiders.

NYSE HAE opened at $124.66 on Tuesday. The company has a quick ratio of 1.34, a current ratio of 2.10 and a debt-to-equity ratio of 0.54. Haemonetics Co. has a twelve month low of $80.24 and a twelve month high of $140.36. The firm has a market capitalization of $6.39 billion, a PE ratio of 52.16, a P/E/G ratio of 3.02 and a beta of 0.79. The stock’s 50 day moving average is $128.81 and its 200 day moving average is $111.68.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Tuesday, August 6th. The medical instruments supplier reported $0.81 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.63 by $0.18. Haemonetics had a return on equity of 21.07% and a net margin of 5.05%. The company had revenue of $238.50 million for the quarter, compared to analyst estimates of $236.82 million. During the same period in the previous year, the company posted $0.59 earnings per share. The firm’s revenue was up 4.0% on a year-over-year basis. On average, research analysts anticipate that Haemonetics Co. will post 3.09 earnings per share for the current year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides hematology products and solutions. The company operates through five segments: North America Plasma; Americas Blood Center and Hospital; Europe, Middle East and Africa; Asia Pacific; and Japan. It offers automated plasma collection devices and related disposables, including NexSys PCS plasmapheresis system and PCS2 equipment and disposables, plasma collection containers, and intravenous solutions, as well as information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system.

Read More: Short Selling Stocks and Day Traders

Institutional Ownership by Quarter for Haemonetics (NYSE:HAE)

Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.